Biotron Limited Logo

Biotron Limited

BIT.AX

(0.5)
Stock Price

0,02 AUD

-84.47% ROA

-159.6% ROE

-27.08x PER

Market Cap.

99.250.306,00 AUD

1.43% DER

0% Yield

0% NPM

Biotron Limited Stock Analysis

Biotron Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Biotron Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (7%), which means it has a small amount of debt compared to the ownership it holds

2 ROE

The stock's ROE indicates a negative return (-140.97%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-183.25%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (59.04x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Biotron Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Biotron Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Biotron Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Biotron Limited Revenue
Year Revenue Growth
1999 0
2000 13.060 100%
2001 62.740 79.18%
2002 0 0%
2003 0 0%
2004 0 0%
2005 794.862 100%
2006 402.457 -97.5%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 931 100%
2018 1.072.832 99.91%
2019 50.000 -2045.66%
2020 50.000 0%
2020 0 0%
2021 0 0%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Biotron Limited Research and Development Expenses
Year Research and Development Expenses Growth
1999 0
2000 542.241 100%
2001 1.063.000 48.99%
2002 1.197.012 11.2%
2003 2.081.410 42.49%
2004 1.404.084 -48.24%
2005 1.875.449 25.13%
2006 2.412.418 22.26%
2007 1.303.421 -85.08%
2008 980.294 -32.96%
2009 965.313 -1.55%
2010 1.159.336 16.74%
2011 1.729.015 32.95%
2012 3.545.476 51.23%
2013 3.237.229 -9.52%
2014 2.882.954 -12.29%
2015 3.132.197 7.96%
2016 3.155.423 0.74%
2017 1.692.656 -86.42%
2018 1.115.879 -51.69%
2019 2.857.383 60.95%
2020 2.857.383 0%
2020 3.136.626 8.9%
2021 2.821.142 -11.18%
2022 4.035.812 30.1%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Biotron Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 448.405 100%
2001 609.000 26.37%
2002 927.743 34.36%
2003 1.013.786 8.49%
2004 857.305 -18.25%
2005 870.102 1.47%
2006 873.047 0.34%
2007 791.696 -10.28%
2008 584.097 -35.54%
2009 634.739 7.98%
2010 961.167 33.96%
2011 1.069.116 10.1%
2012 1.084.895 1.45%
2013 1.199.958 9.59%
2014 1.187.061 -1.09%
2015 1.138.749 -4.24%
2016 1.145.310 0.57%
2017 1.170.736 2.17%
2018 299.580 -290.79%
2019 1.124.096 73.35%
2020 1.124.096 0%
2020 1.132.182 0.71%
2021 1.116.348 -1.42%
2022 480.564 -132.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Biotron Limited EBITDA
Year EBITDA Growth
1999 0
2000 -1.527.987 100%
2001 -1.672.000 8.61%
2002 -2.442.190 31.54%
2003 -3.329.695 26.65%
2004 -2.499.957 -33.19%
2005 -3.010.694 16.96%
2006 -3.338.475 9.82%
2007 -2.348.191 -42.17%
2008 -1.792.343 -31.01%
2009 -1.892.128 5.27%
2010 -2.406.785 21.38%
2011 -3.082.571 21.92%
2012 -4.946.200 37.68%
2013 -4.867.074 -1.63%
2014 -4.426.220 -9.96%
2015 -4.613.396 4.06%
2016 -4.769.456 3.27%
2017 -3.220.240 -48.11%
2018 -1.688.472 -90.72%
2019 -3.520.722 52.04%
2020 -3.520.722 0%
2020 -3.145.750 -11.92%
2021 -2.730.779 -15.2%
2022 -5.573.092 51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Biotron Limited Gross Profit
Year Gross Profit Growth
1999 0
2000 13.060 100%
2001 62.740 79.18%
2002 0 0%
2003 0 0%
2004 0 0%
2005 794.862 100%
2006 402.457 -97.5%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 931 100%
2018 1.072.832 99.91%
2019 50.000 -2045.66%
2020 50.000 0%
2020 0 0%
2021 0 0%
2022 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Biotron Limited Net Profit
Year Net Profit Growth
1999 0
2000 -1.280.000 100%
2001 -1.667.000 23.22%
2002 -2.728.701 38.91%
2003 0 0%
2004 -1.883.575 100%
2005 -2.198.973 14.34%
2006 -3.234.004 32%
2007 -1.882.093 -71.83%
2008 -1.776.099 -5.97%
2009 -1.872.244 5.14%
2010 -1.907.527 1.85%
2011 -2.378.052 19.79%
2012 -3.850.745 38.24%
2013 -3.085.814 -24.79%
2014 -2.723.221 -13.31%
2015 -3.004.303 9.36%
2016 -3.093.405 2.88%
2017 -1.593.645 -94.11%
2018 -1.611.799 1.13%
2019 -3.575.959 54.93%
2020 -3.575.959 0%
2020 -4.657.553 23.22%
2021 -2.786.132 -67.17%
2022 -5.398.352 48.39%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Biotron Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Biotron Limited Free Cashflow
Year Free Cashflow Growth
2000 -1.583.615
2001 -2.163.391 26.8%
2002 -80.479 -2588.14%
2003 -2.760.802 97.08%
2004 -1.711.241 -61.33%
2005 -1.788.636 4.33%
2006 -3.647.321 50.96%
2007 -1.684.580 -116.51%
2008 -1.892.243 10.97%
2009 -1.858.310 -1.83%
2010 -1.970.559 5.7%
2011 -2.290.104 13.95%
2012 -3.099.344 26.11%
2013 -3.028.256 -2.35%
2014 -2.719.700 -11.35%
2015 -3.085.670 11.86%
2016 -2.838.992 -8.69%
2017 0 0%
2018 -1.538.824 100%
2019 -3.081.822 50.07%
2020 -3.413.320 9.71%
2021 -2.436.048 -40.12%
2022 -1.234.031 -97.41%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Biotron Limited Operating Cashflow
Year Operating Cashflow Growth
2000 -1.310.615
2001 -1.682.391 22.1%
2002 0 0%
2003 -2.605.850 100%
2004 -1.710.695 -52.33%
2005 -1.787.424 4.29%
2006 -3.645.129 50.96%
2007 -1.622.319 -124.69%
2008 -1.892.243 14.26%
2009 -1.858.310 -1.83%
2010 -1.968.741 5.61%
2011 -2.287.852 13.95%
2012 -3.090.611 25.97%
2013 -2.975.848 -3.86%
2014 -2.719.700 -9.42%
2015 -3.080.907 11.72%
2016 -2.833.497 -8.73%
2017 0 0%
2018 -1.497.891 100%
2019 -3.081.822 51.4%
2020 -3.407.597 9.56%
2021 -2.436.048 -39.88%
2022 -1.234.031 -97.41%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Biotron Limited Capital Expenditure
Year Capital Expenditure Growth
2000 273.000
2001 481.000 43.24%
2002 80.479 -497.67%
2003 154.952 48.06%
2004 546 -28279.49%
2005 1.212 54.95%
2006 2.192 44.71%
2007 62.261 96.48%
2008 0 0%
2009 0 0%
2010 1.818 100%
2011 2.252 19.27%
2012 8.733 74.21%
2013 52.408 83.34%
2014 0 0%
2015 4.763 100%
2016 5.495 13.32%
2017 0 0%
2018 40.933 100%
2019 0 0%
2020 5.723 100%
2021 0 0%
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Biotron Limited Equity
Year Equity Growth
1999 42.221.000
2000 10.080.657 -318.83%
2001 8.489.713 -18.74%
2002 5.761.012 -47.36%
2003 2.955.897 -94.9%
2004 2.278.730 -29.72%
2005 4.495.848 49.31%
2006 1.356.015 -231.55%
2007 1.843.377 26.44%
2008 841.506 -119.06%
2009 1.717.558 51.01%
2010 2.400.300 28.44%
2011 8.269.547 70.97%
2012 4.475.110 -84.79%
2013 1.389.296 -222.11%
2014 4.143.026 66.47%
2015 3.136.967 -32.07%
2016 1.440.100 -117.83%
2017 1.281.508 -12.38%
2018 5.438.970 76.44%
2019 6.973.008 22%
2020 3.862.994 -80.51%
2021 1.092.496 -253.59%
2022 3.172.656 65.57%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Biotron Limited Assets
Year Assets Growth
1999 42.221.000
2000 10.192.106 -314.25%
2001 8.632.608 -18.07%
2002 5.909.088 -46.09%
2003 3.109.230 -90.05%
2004 2.428.608 -28.03%
2005 4.813.956 49.55%
2006 1.519.038 -216.91%
2007 2.267.322 33%
2008 1.063.838 -113.13%
2009 1.857.845 42.74%
2010 2.644.620 29.75%
2011 8.461.726 68.75%
2012 4.866.189 -73.89%
2013 1.863.940 -161.07%
2014 4.616.202 59.62%
2015 3.483.283 -32.52%
2016 2.059.610 -69.12%
2017 1.619.210 -27.2%
2018 5.856.968 72.35%
2019 7.826.201 25.16%
2020 4.326.504 -80.89%
2021 1.906.061 -126.99%
2022 4.135.150 53.91%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Biotron Limited Liabilities
Year Liabilities Growth
1999 0
2000 111.449 100%
2001 142.895 22.01%
2002 148.076 3.5%
2003 153.333 3.43%
2004 149.878 -2.31%
2005 318.108 52.88%
2006 163.023 -95.13%
2007 423.945 61.55%
2008 222.332 -90.68%
2009 140.287 -58.48%
2010 244.320 42.58%
2011 192.179 -27.13%
2012 391.079 50.86%
2013 474.644 17.61%
2014 473.176 -0.31%
2015 346.316 -36.63%
2016 619.510 44.1%
2017 337.702 -83.45%
2018 417.998 19.21%
2019 853.193 51.01%
2020 463.510 -84.07%
2021 813.565 43.03%
2022 962.494 15.47%

Biotron Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-27.08x
Price To Sales Ratio
69.34x
POCF Ratio
-28.75
PFCF Ratio
-30.17
Price to Book Ratio
29.82
EV to Sales
66.59
EV Over EBITDA
-26.63
EV to Operating CashFlow
-28.97
EV to FreeCashFlow
-28.97
Earnings Yield
-0.04
FreeCashFlow Yield
-0.03
Market Cap
0,10 Bil.
Enterprise Value
0,10 Bil.
Graham Number
0.02
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.94
ROE
-1.05
Return On Assets
-1.61
Return On Capital Employed
-3.08
Net Income per EBT
0.71
EBT Per Ebit
0.98
Ebit per Revenue
0
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.49
Research & Developement to Revenue
2.26
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.11
Return on Tangible Assets
-0.84
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
1.1
Current Ratio
4.22
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.01
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Biotron Limited Dividends
Year Dividends Growth

Biotron Limited Profile

About Biotron Limited

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.

CEO
Dr. Michelle Miller BSc., GCe
Employee
4
Address
66 Hunter Street
Sydney, 2000

Biotron Limited Executives & BODs

Biotron Limited Executives & BODs
# Name Age
1 Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D.
MD & Executive Director
70
2 Mr. Peter James Nightingale B.Econ, CA
Company Secretary
70
3 Dr. Stephen L. Becker M.D.
Chief Medical Officer
70

Biotron Limited Competitors